Drug intelligence / Profile preview

CSD500

Development stage
Unknown
Lead developer
Futura Medical
Modality
Small Molecules, Device-based Delivery → Drug Delivery Systems
Administration
Topical
01

Overview

CSD500 is an erectogenic condom developed by Futura Medical and licensed to Reckitt Benckiser for sale under the Durex brand, most notably as Durex Blue Diamond. The product is a medical device that incorporates a proprietary vasodilator gel called Zanifil, which contains the active ingredient glyceryl trinitrate (nitroglycerin), within the tip of the condom. Upon application, the gel is absorbed through the skin of the penis, acting as a nitric oxide donor to stimulate local vasodilation and increase blood flow. This mechanism is designed to help men maintain firmer, larger, and longer-lasting erections during intercourse, potentially encouraging condom use for contraception and the prevention of sexually transmitted infections. CSD500 has received CE mark approval in Europe and is marketed in several regions, including the Middle East and North Africa.

Brand names
Durex Blue Diamond
Other names
ZanifilErectogenic Condom
02

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on CSD500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSD500.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call